PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · South Asian J Cancer 2018; 07(03): 194-202
DOI: 10.4103/sajc.sajc_199_18
Letter to the Editor

Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer

Autor*innen

  • Swaratika Majumdar

    Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra

  • Vanita Noronha

    Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra

  • Amit Joshi

    Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra

  • Vijay Patil

    Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra

  • Rajiv Kumar

    Department of Pathology, Tata Memorial Hospital, Mumbai, Maharashtra

  • Vaibhavi Trivedi

    Department of Pathology, Tata Memorial Hospital, Mumbai, Maharashtra

  • Kumar Prabhash

    Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra

Source of Support: Nill.
Weitere Informationen
Auch verfügbar auf
 als PDF herunterladen Lizenzen und Reprints
Preview Container


Publikationsverlauf

Artikel online veröffentlicht:
22. Dezember 2020

© 2018. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: A single-group, multicentre, phase 2 trial. Lancet Oncol 2016;17:234-42.
  • 2 Mezquita L, Besse B. Sequencing ALK inhibitors: Alectinib in crizotinib-resistant patients, a phase 2 trial by Shaw et al. J Thorac Dis 2016;8:2997-3002.
  • 3 Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: A phase II global study. J Clin Oncol 2016;34:661-8.